Empagliflozin 25 mg + Sitagliptin 100 mg is a prescription medication designed for the management of type 2 diabetes mellitus. This combination therapy works synergistically to regulate blood glucose levels. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that helps lower blood sugar by promoting glucose excretion through urine. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the body’s own ability to lower elevated blood sugar by increasing insulin release and decreasing glucagon levels. Together, these agents provide effective glycemic control, improve HbA1c levels, and can aid in weight management and cardiovascular health in patients with type 2 diabetes.
